Literature DB >> 2310674

Preliminary observations on the microdistribution of labelled antibodies in human colonic adenocarcinoma xenografts: relevance to microdosimetry.

R B Pedley1, G M Boxer, J A Boden, P J Southall, R H Begent, K D Bagshawe, J Humm, F Searle.   

Abstract

Autoradiography with 125I-labelled antibodies 17-1-A and 11-285-14 (anti-carcinoembryonic antigen) injected singly or together into nude mice carrying two distinct human colorectal cancer xenografts delineates marked changes in distribution and retention of isotope over 72 h, which are relevant to microdosimetry. The antibodies localise independently at low concentrations. Slow accumulation and retention predominantly in membranes of glands and necrotic areas suggest that therapy will succeed best with isotopes whose range, half-life and/or mode of delivery can exploit optimally the greater selectivity of the late retention.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2310674      PMCID: PMC1971400          DOI: 10.1038/bjc.1990.40

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  8 in total

1.  The use of paired labeling in the determination of tumor-localizing antibodies.

Authors:  D PRESSMAN; E D DAY; M BLAU
Journal:  Cancer Res       Date:  1957-10       Impact factor: 12.701

2.  Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy.

Authors:  R W Kozak; R W Atcher; O A Gansow; A M Friedman; J J Hines; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

3.  Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy.

Authors:  M H Griffith; E D Yorke; B W Wessels; G L DeNardo; W P Neacy
Journal:  J Nucl Med       Date:  1988-11       Impact factor: 10.057

4.  A comparison of the content and immunohistochemical patterns of CEA-like activity in human colorectal tumours and nude mouse xenografts.

Authors:  J C Lewis; P A Smith; P A Keep; G M Boxer
Journal:  Exp Pathol       Date:  1983

5.  Radioimmunodetection of human tumor xenografts by monoclonal antibodies.

Authors:  D Herlyn; J Powe; A Alavi; J A Mattis; M Herlyn; C Ernst; R Vaum; H Koprowski
Journal:  Cancer Res       Date:  1983-06       Impact factor: 12.701

6.  The comparative distribution of monoclonal antibodies to CEA in colorectal xenografts.

Authors:  J C Lewis; G M Boxer; F Searle; K D Bagshawe
Journal:  Tumour Biol       Date:  1984

7.  Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer.

Authors:  R H Begent; J A Ledermann; A J Green; K D Bagshawe; S J Riggs; F Searle; P A Keep; T Adam; R G Dale; M G Glaser
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

8.  The effect of serum CEA on the distribution and clearance of anti-CEA antibody in a pancreatic tumour xenograft model.

Authors:  R B Pedley; J A Boden; R W Boden; A Green; G M Boxer; K D Bagshawe
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

  8 in total
  3 in total

Review 1.  Monoclonal antibody administration. Current clinical pharmacokinetic status and future trends.

Authors:  R H Begent; R B Pedley; J Begent
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

2.  Factors influencing variability of localisation of antibodies to carcinoembryonic antigen (CEA) in patients with colorectal carcinoma--implications for radioimmunotherapy.

Authors:  G M Boxer; R H Begent; A M Kelly; P J Southall; S B Blair; N A Theodorou; P M Dawson; J A Ledermann
Journal:  Br J Cancer       Date:  1992-06       Impact factor: 7.640

3.  Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA)--implications for targeted therapy.

Authors:  G M Boxer; A M Abassi; R B Pedley; R H Begent
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.